Takeda Pharmaceutical Company Limited vs Dr. Reddy's Laboratories Limited: A Gross Profit Performance Breakdown

Pharmaceutical Giants: A Decade of Gross Profit Trends

__timestampDr. Reddy's Laboratories LimitedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014758010000001256834000000
Thursday, January 1, 2015854030000001271973000000
Friday, January 1, 2016922810000001173296000000
Sunday, January 1, 2017783560000001274610000000
Monday, January 1, 2018763040000001437534000000
Tuesday, January 1, 2019834300000002201424000000
Wednesday, January 1, 2020940090000002203504000000
Friday, January 1, 20211030770000002462160000000
Saturday, January 1, 20221138400000002783406000000
Sunday, January 1, 20232029720000002832257000000
Monday, January 1, 20241636070000002832257000000
Loading chart...

In pursuit of knowledge

A Tale of Two Giants: Gross Profit Trends in Pharmaceuticals

In the competitive world of pharmaceuticals, Takeda Pharmaceutical Company Limited and Dr. Reddy's Laboratories Limited have showcased intriguing gross profit trajectories over the past decade. From 2014 to 2024, Takeda's gross profit surged by approximately 125%, peaking at an impressive $2.83 trillion in 2023. This growth reflects Takeda's strategic expansions and robust market presence.

Conversely, Dr. Reddy's Laboratories experienced a more modest growth of around 115% during the same period, reaching a gross profit of $203 billion in 2023. Despite the difference in scale, Dr. Reddy's consistent upward trend highlights its resilience and adaptability in a dynamic market.

These figures underscore the contrasting strategies and market dynamics faced by these pharmaceutical titans, offering valuable insights into their financial health and future prospects.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025